Show simple item record

dc.contributor.authorEl Sawy, I.H.
dc.contributor.authorMohamed, O.N.
dc.date.accessioned2014-06-17T10:39:57Z
dc.date.available2014-06-17T10:39:57Z
dc.date.issued1999EN
dc.identifier.issn1020-3397EN
dc.identifier.otherhttp://applications.emro.who.int/emhj/0505/emhj_1999_5_5_922_932.pdfEN
dc.identifier.urihttps://apps.who.int/iris/handle/10665/118780
dc.description922-932EN
dc.description.abstractIn 1992, Egypt adopted a hepatitis B vaccine schedule at 2, 4 and 6 months of age. We evaluated the long-term immunogenicity and efficacy of vaccination using this schedule in 180 children whose time lapse since last vaccination varied between 1 month and 5 years. None of the participants had clinical hepatitis, HBsAg was not detected in any participant and all but one had negative results for anti-HBc test. Although a high seroprotection rate [‎93.3%]‎ was elicited 1 month after vaccination, there were low initial anti-HBs concentrations and both declined rapidly over time. Thus, the short interval [‎2 months]‎ between the second and third doses of vaccine is less desirable in the long term. We recommend booster inoculations for all previously vaccinated children and a new vaccination schedule at 1, 2 and 9 monthsEN
dc.language.isoenEN
dc.subjectChild, PreschoolEN
dc.subjectCross-Sectional StudiesEN
dc.subjectHepatitis B AntibodiesEN
dc.subjectHepatitis B Core AntigensEN
dc.subjectHepatitis B Surface AntigensEN
dc.subjectImmunization ScheduleEN
dc.subjectImmunization, SecondaryEN
dc.subjectTime FactorsEN
dc.subjectVaccines, SyntheticEN
dc.subject.meshHepatitis B VaccinesEN
dc.titleLong-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian childrenEN
dc.relation.ispartofjournalEMHJ - Eastern Mediterranean Health Journal, 5 (‎5)‎, 922-932, 1999


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record